Unicycive Therapeutics Inc UNCY

Healthcare Biotechnology

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee’s Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum ...

NDAQ:UNCY - Post by User

Unicycive Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

(657)
•••

Post by Iseneschalon Mar 10, 2023 9:04am

120 Views

Post# 35330111

UNCY .....The trend continues....Day 6 of run....Sheesh

Close Prices Last 3 Months

Price/volumes not adjusted for restructures

Date	Ex	Sym	Open	High	Low	Close	Chg	Vol	#Tr	Bid	Ask
2023-03-09	Q	UNCY	1.91	2.24	1.76	2.06	0.44	46,695,686	51,175
2023-03-08	Q	UNCY	1.44	1.75	1.35	1.62	0.12	12,134,258	14,231
2023-03-07	Q	UNCY	1.46	2.16	1.37	1.50	0.26	89,437,509	103,573
2023-03-06	Q	UNCY	1.41	1.63	1.13	1.24	0.75	102,922,506	98,143
2023-03-03	Q	UNCY	0.511	0.52	0.48	0.49	-0.01	70,241	107